AR099883A1 - Computadora y métodos relacionados con el diagnóstico de cáncer de próstata - Google Patents

Computadora y métodos relacionados con el diagnóstico de cáncer de próstata

Info

Publication number
AR099883A1
AR099883A1 ARP150100936A ARP150100936A AR099883A1 AR 099883 A1 AR099883 A1 AR 099883A1 AR P150100936 A ARP150100936 A AR P150100936A AR P150100936 A ARP150100936 A AR P150100936A AR 099883 A1 AR099883 A1 AR 099883A1
Authority
AR
Argentina
Prior art keywords
subject
prostate
tpsa
prostate cancer
biopsy
Prior art date
Application number
ARP150100936A
Other languages
English (en)
Inventor
Steinmiller David
Linder Vincent
Pettersson Kim
Lovgren Timo
Lilja Hans
T Scardino Peter
j vickers Andrew
Original Assignee
Opko Diagnostics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Diagnostics Llc filed Critical Opko Diagnostics Llc
Publication of AR099883A1 publication Critical patent/AR099883A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

Reivindicación 1: Un método para determinar la probabilidad de que una biopsia de tejido de próstata que se obtuvo de un sujeto pueda contener cáncer de próstata detectable, caracterizado porque el método comprende: i) someter una muestra de plasma sanguíneo del sujeto a un inmunoensayo que mide un nivel de antígeno prostático específico total (tPSA) en la muestra de plasma sanguíneo; ii) si el nivel de tPSA está por encima de un nivel umbral, determinar la probabilidad de que la biopsia de tejido de próstata pudiese contener cáncer de próstata detectable mediante la ponderación del nivel medido de tPSA y un parámetro indicativo de si el sujeto ha tenido una biopsia previa de tejido de próstata; y iii) si el nivel de tPSA está en el nivel umbral o por debajo del mismo, someter la muestra de plasma sanguíneo a un inmunoensayo que mide los niveles de antígeno prostático específico libre (fPSA), antígeno prostático específico intacto (iPSA), y calicreína humana 2 (hK2) en la muestra de plasma sanguíneo, y determinar la probabilidad de que la biopsia de tejido de próstata pudiese contener cáncer de próstata detectable por ponderación de los niveles medidos de tPSA, fPSA, iPSA, y hK2 y un parámetro indicativo de si el sujeto ha tenido una biopsia previa de tejido de próstata. Reivindicación 39: Una computadora para determinar una probabilidad de un evento asociado con el cáncer de próstata, caracterizado porque la computadora comprende: una interfaz de entrada configurada para recibir información indicativa del nivel de tPSA presente en un muestra de plasma sanguíneo de un sujeto e información sobre si el sujeto tuvo una biopsia previa de tejido de próstata; por lo menos un procesador programado para evaluar un modelo de regresión logística en base a, al menos en parte, la información recibida para determinar una probabilidad de un evento asociado con el cáncer de próstata en el sujeto en donde evaluar el modelo de regresión logística comprende: determinar la probabilidad del evento asociado con el cáncer de próstata en base, al menos en parte, el valor de tPSA y la información sobre si el sujeto tuvo una biopsia previa de tejido de próstata; y una interfaz de salida configurada para proveer una indicación de la probabilidad del evento asociado con el cáncer de próstata.
ARP150100936A 2014-03-28 2015-03-30 Computadora y métodos relacionados con el diagnóstico de cáncer de próstata AR099883A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461972099P 2014-03-28 2014-03-28

Publications (1)

Publication Number Publication Date
AR099883A1 true AR099883A1 (es) 2016-08-24

Family

ID=54196462

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100936A AR099883A1 (es) 2014-03-28 2015-03-30 Computadora y métodos relacionados con el diagnóstico de cáncer de próstata

Country Status (25)

Country Link
US (2) US11761962B2 (es)
EP (2) EP3299977A1 (es)
JP (3) JP6775488B2 (es)
KR (1) KR102505543B1 (es)
CN (2) CN106663149A (es)
AR (1) AR099883A1 (es)
AU (1) AU2015237270B2 (es)
BR (1) BR112016022407A2 (es)
CA (1) CA2944001C (es)
CL (1) CL2016002419A1 (es)
DE (1) DE202015009668U1 (es)
DK (1) DK3123381T3 (es)
EA (1) EA201691952A1 (es)
ES (1) ES2964706T3 (es)
FI (1) FI3123381T3 (es)
HU (1) HUE065029T2 (es)
IL (2) IL247981B (es)
MX (2) MX2016012667A (es)
MY (1) MY192513A (es)
PE (1) PE20170298A1 (es)
PL (1) PL3123381T3 (es)
PT (1) PT3123381T (es)
SG (2) SG10201808585TA (es)
TW (1) TWI687688B (es)
WO (1) WO2015148979A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2687620T3 (es) 2007-05-04 2018-10-26 Opko Diagnostics, Llc Dispositivo y método para análisis en sistemas microfluídicos
TR201815133T4 (tr) 2009-02-02 2018-11-21 Opko Diagnostics Llc Mikrofilidik cihazlar ile ışık etkileşiminin kontrol edilmesi için yapılar.
BR112014021776B1 (pt) 2012-03-05 2022-08-09 Opko Diagnostics, Llc Sistema de ensaio e método para a determinação de uma probabilidade de um evento associado com o câncer da próstata
CN107406510B (zh) 2015-03-27 2022-02-18 欧普科诊断有限责任公司 前列腺抗原标准品及其用途
JP6916797B2 (ja) * 2015-10-05 2021-08-11 フレダックス・アクチエボラーグ 抗体ポリペプチド及びそれらの使用
CA3005084A1 (en) 2015-12-11 2017-06-15 Opko Diagnostics, Llc Fluidic systems involving incubation of samples and/or reagents
HUE055156T2 (hu) 2015-12-29 2021-11-29 Opko Diagnostics Llc Folyadékgyûjtési eszköz és kapcsolódó módszerek
AU2018205280A1 (en) * 2017-01-08 2019-08-15 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Systems and methods for using supervised learning to predict subject-specific pneumonia outcomes
KR102052398B1 (ko) 2018-04-18 2019-12-05 (주)유로테크 전립선암 진단용 바이오마커 및 이의 용도
WO2020205204A1 (en) 2019-04-03 2020-10-08 Opko Diagnostics, Llc Methods for the detection of prostate cancer
KR20240022906A (ko) * 2022-08-12 2024-02-20 (주)맥시온 암 진단용 다중 바이오마커 및 이의 용도

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
SE9002480D0 (sv) 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
EP0635575A1 (en) 1993-07-22 1995-01-25 Wallac Oy Monoclonal antibodies against epitopes found in free but not in alpha-1-antichmotrypsin complexed prostate specific antigen
US5516639A (en) 1993-07-22 1996-05-14 Mayo Foundation For Medical Education And Research Antibodies specific for human prostate glandular kallkrein
WO1995011621A1 (en) 1993-10-28 1995-05-04 I-Stat Corporation Fluid sample collection and introduction device
US5599677A (en) 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
US5585069A (en) 1994-11-10 1996-12-17 David Sarnoff Research Center, Inc. Partitioned microelectronic and fluidic device array for clinical diagnostics and chemical synthesis
US5614372A (en) 1995-02-24 1997-03-25 Lilja; Hans Early detection of prostate cancer (CAP) by employing prostate specific antigen (PSA) and human glandular kallikrein (hGK-1)
CA2228485A1 (en) 1995-08-03 1997-02-20 Akzo Nobel Nv Diagnostic device
US6143509A (en) 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
WO1997039351A1 (en) 1996-04-12 1997-10-23 Carter Herbert B Novel methods for the prediction and early detection of prostatic adenocarcinoma
US5840501A (en) 1996-10-25 1998-11-24 Bayer Corporation Determination of cPSA
US5945289A (en) 1996-12-20 1999-08-31 Lehrer; Steven Method for detecting prostate cancer by apolipoprotein E (Apo-E) genotyping
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
SE9704934D0 (sv) 1997-12-30 1997-12-30 Pharmacia & Upjohn Diag Ab Analysförfarande med tillsättning i två eller flera positioner
FI980488A (fi) 1998-03-04 1999-09-05 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
FR2780791B1 (fr) 1998-07-03 2000-09-01 Bio Merieux Methode de depistage ou de diagnostic d'un adenocarcinome ou d'une pathologie benigne de la prostate et procede de mise en oeuvre
CA2360073C (en) 1999-01-28 2011-01-18 Gen-Probe Incorporated Probes and primers for detecting prostate specific antigen (psa) in a biological sample
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US7211397B2 (en) 1999-04-30 2007-05-01 Beckman Coulter, Inc. Method of analyzing non-complexed forms of prostate specific antigen in a sample to improve prostate cancer detection
US6136549A (en) 1999-10-15 2000-10-24 Feistel; Christopher C. systems and methods for performing magnetic chromatography assays
FI20002127A0 (fi) 2000-09-27 2000-09-27 Artic Partners Oy Ab Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
US20020076825A1 (en) 2000-10-10 2002-06-20 Jing Cheng Integrated biochip system for sample preparation and analysis
DE60128404D1 (de) 2000-11-20 2007-06-21 Eastern Virginia Med School Verfahren und vorrichtungen zum quantitativen nachweis eines prostata-spezifischen membranantigens und anderer prostatamarker
AU2002362447A1 (en) 2001-10-03 2003-04-14 University Of Rochester Human glandular kallikrein (hk2)-specific monoclonal antibodies that enhance or inhibit the enzymatic activity of hk2
US7258837B2 (en) 2001-12-05 2007-08-21 University Of Washington Microfluidic device and surface decoration process for solid phase affinity binding assays
US20030235816A1 (en) 2002-03-14 2003-12-25 Baylor College Of Medicine (By Slawin And Shariat) Method to determine outcome for patients with prostatic disease
US20050272052A1 (en) 2002-04-09 2005-12-08 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
JPWO2003100425A1 (ja) 2002-05-28 2005-11-04 株式会社常光 免疫学的クロマトグラフ法の試験紙片の読み取り定量装置
KR20110019357A (ko) 2002-08-06 2011-02-25 더 존스 홉킨스 유니버시티 난소암의 검출을 위한 생물 마커의 용도
US20040115794A1 (en) 2002-12-12 2004-06-17 Affymetrix, Inc. Methods for detecting transcriptional factor binding sites
US20050282170A1 (en) * 2003-02-07 2005-12-22 Diagnocure Inc. Method to detect prostate cancer in a sample
US7461048B2 (en) 2003-07-21 2008-12-02 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
US20060269971A1 (en) 2003-09-26 2006-11-30 Mount Sinai Hospital Methods for detecting prostate cancer
US20050118061A1 (en) 2003-11-28 2005-06-02 Sysmex Corporation Analyzer, assay cartridge and analyzing method
EP1691924B1 (en) 2003-12-10 2016-09-14 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin A modular biochip assembly
CA2564609C (en) 2003-12-31 2014-02-11 President And Fellows Of Harvard College Assay device and method
ES2439225T3 (es) 2004-01-26 2014-01-22 President And Fellows Of Harvard College Sistema y método para el suministro de fluidos
US8030057B2 (en) 2004-01-26 2011-10-04 President And Fellows Of Harvard College Fluid delivery system and method
TW200538734A (en) 2004-03-12 2005-12-01 Aureon Biosciences Corp Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
WO2005111625A2 (en) 2004-05-11 2005-11-24 Baylor College Of Medicine Method to predict prostate cancer
US20060154276A1 (en) 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
MX2007001357A (es) 2004-08-02 2009-08-07 Childrens Medical Center Biomarcadores de plaquetas para cancer.
CA2580494A1 (en) 2004-09-17 2006-03-30 The Johns Hopkins University Biomarkers for breast cancer
US8663600B2 (en) 2005-02-17 2014-03-04 Diaprost Ab Diagnosis of prostate cancer
WO2006122311A2 (en) 2005-05-11 2006-11-16 The Trustees Of The University Of Pennsylvania Microfluidic chip
US20070065954A1 (en) 2005-09-15 2007-03-22 Minoru Taya Surface plasmon resonance biosensor system for detection of antigens and method for determining the presence of antigens
BRPI0709176A2 (pt) 2006-03-24 2011-06-28 Phenomenome Discoveries Inc biomarcadores úteis para diagnosticar o cáncer de próstata e seus métodos
AU2007271232A1 (en) 2006-07-03 2008-01-10 Exonhit Therapeutics Sa Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics
CN1973778A (zh) 2006-12-08 2007-06-06 南京大学 胃癌术后严重并发症风险度的预测方法
EP2106262B1 (en) 2006-12-22 2015-11-18 Phadia AB Novel prostate kallikrein allergen
ES2687620T3 (es) 2007-05-04 2018-10-26 Opko Diagnostics, Llc Dispositivo y método para análisis en sistemas microfluídicos
AU2008251877A1 (en) 2007-05-08 2008-11-20 Picobella Llc Methods for diagnosing and treating prostate and lung cancer
CN101329343A (zh) 2007-06-19 2008-12-24 天津迪爱盟生物技术有限公司 新一代早期诊断前列腺癌试剂盒及其制备方法和检测方法
US20090087860A1 (en) 2007-08-24 2009-04-02 Todd John A Highly sensitive system and methods for analysis of prostate specific antigen (psa)
CN101377500A (zh) 2007-08-31 2009-03-04 北京科美东雅生物技术有限公司 游离前列腺特异性抗原化学发光免疫分析测定试剂盒及其制备方法
ES2543985T3 (es) 2007-10-22 2015-08-26 St Vincent's Hospital Sydney Limited Métodos de pronóstico
US20090226912A1 (en) 2007-12-21 2009-09-10 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
JP5028697B2 (ja) 2008-02-18 2012-09-19 富士フイルム株式会社 吸引シリンジ及び内視鏡用吸引シリンジ
EP2281201B1 (en) 2008-05-14 2018-03-28 ETH Zurich Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith
FR2934698B1 (fr) 2008-08-01 2011-11-18 Commissariat Energie Atomique Procede de prediction pour le pronostic ou le diagnostic ou la reponse therapeutique d'une maladie et notamment du cancer de la prostate et dispositif permettant la mise en oeuvre du procede.
CA2741034C (en) 2008-10-20 2021-06-22 Liposcience, Inc. Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same
EP2370813A4 (en) 2008-12-04 2012-05-23 Univ California MATERIALS AND METHODS FOR DIAGNOSIS AND PROGNOSIS OF PROSTATE CANCER
EP2376226B1 (en) 2008-12-18 2018-09-12 Opko Diagnostics, LLC Improved reagent storage in microfluidic systems and related articles and methods
WO2010075446A1 (en) 2008-12-23 2010-07-01 Soar Biodynamics, Ltd. Methods and systems for prostate health monitoring
US20120022793A1 (en) 2009-01-19 2012-01-26 Miraculins, Inc. Biomarkers for the diagnosis of prostate cancer in a non-hypertensive population
TR201815133T4 (tr) 2009-02-02 2018-11-21 Opko Diagnostics Llc Mikrofilidik cihazlar ile ışık etkileşiminin kontrol edilmesi için yapılar.
JP2010243406A (ja) 2009-04-08 2010-10-28 F Hoffmann La Roche Ag Ａｆｐおよびｐｉｖｋａ−ｉｉの測定値を特徴値とした識別関数を利用する、肝臓癌および慢性肝疾患の病態進行度の検出方法
WO2010127322A1 (en) 2009-05-01 2010-11-04 Genomic Health Inc. Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy
WO2010139711A1 (en) * 2009-06-04 2010-12-09 Metanomics Health Gmbh Means and methods for diagnosing prostate carcinomas
WO2011027310A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
WO2011027308A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
KR101141190B1 (ko) * 2009-10-19 2012-06-13 중앙대학교 산학협력단 전립선암에 대한 바이오마커 및 이를 이용한 전립선암 진단
CN102844332B (zh) * 2010-03-11 2015-08-19 瑞纳神经科学公司 呈pH依赖性抗原结合的抗体
WO2011130629A1 (en) 2010-04-16 2011-10-20 Claros Diagnostics, Inc. Systems and devices for analysis of samples
WO2012029080A1 (en) 2010-08-30 2012-03-08 Decode Genetics Ehf Sequence variants associated with prostate specific antigen levels
BRPI1100857A2 (pt) 2011-03-18 2013-05-21 Alexandre Eduardo Nowill agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
WO2012129408A2 (en) 2011-03-22 2012-09-27 The Johns Hopkins University Biomarkers for aggressive prostate cancer
US20140227720A1 (en) 2011-06-09 2014-08-14 Quanterix Corporation Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
KR101968485B1 (ko) 2011-07-21 2019-04-12 후지필름 와코 준야꾸 가부시키가이샤 혈장중 아미노산 분석용 표준액
BR112014010739A2 (pt) 2011-10-28 2017-04-25 Fredax Ab agentes terapêuticos e uso dos mesmos
WO2013106778A2 (en) 2012-01-13 2013-07-18 Iris International, Inc. Non-equilibrium two-site assays for linear, ultrasensitive analyte detection
BR112014021776B1 (pt) 2012-03-05 2022-08-09 Opko Diagnostics, Llc Sistema de ensaio e método para a determinação de uma probabilidade de um evento associado com o câncer da próstata
WO2013172779A2 (en) * 2012-05-16 2013-11-21 Phadia Ab Method for indicating the presence or non-presence of prostate cancer
NZ703411A (en) 2012-06-27 2017-09-29 Berg Llc Use of markers in the diagnosis and treatment of prostate cancer
CN102818892B (zh) 2012-08-16 2015-02-18 北京恩济和生物科技有限公司 一种前列腺特异性抗原检测试剂盒及其制备方法
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
RU2675370C2 (ru) 2012-11-20 2018-12-19 Пхадиа Аб Способ выявления присутствия или отсутствия агрессивного рака предстательной железы
CA2891394C (en) 2012-11-20 2023-03-14 Phadia Ab Prognostic method for individuals with prostate cancer
EP3553088A1 (en) 2013-11-19 2019-10-16 Fredax AB Humanised anti kallikrein-2 antibody
CA3134289A1 (en) 2014-03-11 2015-09-17 Phadia Ab Method for detecting a solid tumor cancer
US20170089904A1 (en) 2014-03-28 2017-03-30 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
WO2016145331A1 (en) 2015-03-12 2016-09-15 Thermo Finnigan Llc Methods for data-dependent mass spectrometry of mixed biomolecular analytes
CN107406510B (zh) 2015-03-27 2022-02-18 欧普科诊断有限责任公司 前列腺抗原标准品及其用途
TWI766836B (zh) 2015-04-29 2022-06-11 美商Ｏｐｋｏ診斷法有限責任公司 用於主動監測前列腺癌之方法、電腦、系統及電腦可讀儲存媒體
US20190072555A1 (en) 2017-08-14 2019-03-07 Opko Diagnostics, Llc Multiplex assays for evaluating prostate cancer status
EP3794354A4 (en) 2018-05-16 2022-01-12 Opko Diagnostics, LLC METHODS OF DETECTING PROSTATE CANCER ASSOCIATED WITH NEGATIVE RESULTS

Also Published As

Publication number Publication date
KR102505543B1 (ko) 2023-03-02
PT3123381T (pt) 2023-12-22
PL3123381T3 (pl) 2024-02-26
US20160025732A1 (en) 2016-01-28
BR112016022407A2 (pt) 2017-12-12
US20230393137A1 (en) 2023-12-07
AU2015237270A1 (en) 2016-10-20
SG11201608035UA (en) 2016-10-28
IL280039A (en) 2021-03-01
JP6775488B2 (ja) 2020-10-28
CA2944001A1 (en) 2015-10-01
AU2015237270B2 (en) 2021-09-09
CN106663149A (zh) 2017-05-10
CA2944001C (en) 2023-08-15
US11761962B2 (en) 2023-09-19
CL2016002419A1 (es) 2017-03-31
TW201621320A (zh) 2016-06-16
WO2015148979A8 (en) 2016-01-07
EP3123381B1 (en) 2023-10-11
ES2964706T3 (es) 2024-04-09
FI3123381T3 (fi) 2023-11-27
CN114740202A (zh) 2022-07-12
EP3123381A4 (en) 2018-02-21
MY192513A (en) 2022-08-24
IL247981A0 (en) 2016-11-30
JP7256781B2 (ja) 2023-04-12
KR20170008729A (ko) 2017-01-24
DE202015009668U1 (de) 2019-01-21
MX2016012667A (es) 2017-01-09
SG10201808585TA (en) 2018-11-29
HUE065029T2 (hu) 2024-04-28
JP2017515127A (ja) 2017-06-08
JP2023017841A (ja) 2023-02-07
IL247981B (en) 2021-02-28
TWI687688B (zh) 2020-03-11
PE20170298A1 (es) 2017-04-18
DK3123381T3 (da) 2023-11-27
JP2021009157A (ja) 2021-01-28
EA201691952A1 (ru) 2017-05-31
MX2022002365A (es) 2022-04-06
WO2015148979A1 (en) 2015-10-01
EP3123381A1 (en) 2017-02-01
IL280039B (en) 2021-12-01
EP3299977A1 (en) 2018-03-28

Similar Documents

Publication Publication Date Title
AR099883A1 (es) Computadora y métodos relacionados con el diagnóstico de cáncer de próstata
Wang et al. Evaluation of the NMP22 BladderChek test for detecting bladder cancer: a systematic review and meta-analysis
Frost et al. Risk factors for in-hospital post-hip fracture mortality
Penaloza et al. Performance of age‐adjusted D‐dimer cut‐off to rule out pulmonary embolism
WO2016094330A3 (en) Methods and machine learning systems for predicting the liklihood or risk of having cancer
CO2019008390A2 (es) Uso de biomarcadores en la identificación de pacientes con cáncer que serán sensibles al tratamiento con un inhibidor de prmt5.
PE20180930A1 (es) Composiciones y metodos para la vigilancia activa del cancer de prostata
MX2018008421A (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
AR095363A1 (es) Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1
BR112013027122A2 (pt) método e sistema para analisar características de tecido, e, kit
Virani et al. Escalating burden of breast cancer in southern Thailand: analysis of 1990–2010 incidence and prediction of future trends
MX2016013255A (es) Metodos y composiciones para detectar proteinas mal plegadas.
Rodríguez et al. Diagnostic accuracy of prostate cancer antigen 3 (PCA3) prior to first prostate biopsy: A systematic review and meta-analysis
BR112015031729A2 (pt) sistema de classificação, métodos e kit para classificação, prognóstico e tratamento de câncer de mama
BR112014005651A2 (pt) aparelho de diagnóstico
BR112017006315A2 (pt) agente terapêutico, uso de um agente terapêutico, métodos in vitro para determinar se um sujeito com melanoma tem um risco maior de desenvolver metástase, de determinação de um regime de tratamento para um sujeito que sofre de melanoma, de tratamento de um sujeito que sofre de melanoma, ensaio in vitro para predizer o risco aumentado de metástase e kits
Wolfe Fibromyalgia research criteria
Claeson et al. Multiple primary melanomas: a common occurrence in Western Sweden
Song et al. A novel predictive tool for determining the risk of early death from stage IV endometrial carcinoma: a large cohort study
Cano-Palomares et al. Response to initial therapy of differentiated thyroid cancer predicts the long-term outcome better than classical risk stratification systems
MY195697A (en) Method of Prognosing and Predicting Breast Cancer Recurrence, Markers Employed Therein and Kit Thereof
Faber et al. Validation of Surveillance, Epidemiology, and End Results TNM staging for testicular germ cell tumor
Murali et al. Can we better identify thin cutaneous melanomas that are likely to metastasize and cause death?
BR112014017952A8 (pt) Processo para prognosticar in vitro em uma amostra sanguínea a probabilidade para um paciente evoluir para uma dengue severa
BR112018071395A2 (pt) métodos de identificação de pacientes, método de previsão do risco de progressão para lvh, método de diferenciação em pacientes, métodos de previsão se pacientes se encontram com risco de progressão para lvh e uso